Effect of 5637-conditioned medium on peripheral blood granulocyte-macrophage progenitors in normal subjects and patients with the myelodysplastic syndrome

Tennant, G. B.; Jacobs, A.

doi:10.1016/0145-2126(89)90078-7

Cited by 15 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although not routinely available at all centers, these progenitor cell assays can provide a sensitive screening parameter for undiagnosed cytopenias (Tennant, Jacobs et al 1986; Valent 2012). In MDS specifically, they may also have prognostic significance in that low growth suggests a poorer prognosis (Geissler, Hinterberger et al 1988; Shih, Chiu et al 1991).…”

mentioning

confidence: 99%

Burst-forming unit–erythroid assays to distinguish cellular bone marrow failure disorders

DeZern

McDevitt

et al. 2013

Experimental Hematology

View full text Add to dashboard Cite

Patients with cytopenias and a cellular bone marrow can be a diagnostic and a therapeutic challenge. Previous reports have suggested a role for progenitor assays as a potentially useful test for diagnosis and predicting response to therapy. Here we report the results of BFU-E assays in 48 consultative cases of single or multi-lineage cytopenias with cellular marrows. The final diagnoses included 17 patients with myelodysplastic syndrome (MDS); 9 patients with pure red cell aplasia (PRCA) [non-large granular lymphocytosis (LGL) in etiology]; 15 patients with LGL (8 of which had a single lineage cytopenia only while the other 7 had multi-lineage cytopenias); and 7 patients with cytopenias associated with systemic inflammation related to autoimmune conditions. In this cohort, nonmalignant diseases were well-distinguished from MDS by BFU-E growth. Our data suggest that low BFU-E growth (less than 10 BFU-E /105 marrow mononuclear cells) helps to exclude LGL, PRCA, or cytopenias associated with systemic inflammation as a cause of pancytopenia with a sensitivity of 96.8%, specificity of 76.5% and a predictive value of 88.2% (p=0.0001). BFU-E growth was also examined to predict response to treatment. Of the 29 patients in this cohort treated with immunosuppressive therapy across all disease groups, there was an 86% response rate with 25 responders (11 PRs and 14 CRs) and 4 non-responders. This did correlate with higher BFU-E growth. Our results suggest BFU-E assays are a useful adjunct in the diagnosis and management of cytopenias in the setting of a normocellular or hypercellular bone marrows.

show abstract

mentioning

confidence: 99%

Burst-forming unit–erythroid assays to distinguish cellular bone marrow failure disorders

DeZern

McDevitt

et al. 2013

Experimental Hematology

View full text Add to dashboard Cite

show abstract

“…30 Rabbits Gratwohl et al (1995) 0-8 0-39.1 a Dogs Kreja et al (1988) 13-39 53.7-160.9 b K6rblinge et al (1979) 34-280 83-292 Gerhartz and Fliedner (1980) 26. 4_+9~7 Bolin et al (1983) 15 _+8.2 Humans Rubin and Cowan (1973) 22-110 0-35 c Verma et al (1980) 8-6 21 +15.7 c Lacombe et al (1980) 76+154 182.4+369 c Eridani et al (1984) 4+95 9.6+228 c Tennant et al (1986) 4.1+110.5 Biljanovi6 et al (1990) 6+30 14.4+72 c Majolino et al (1995) 39-589 156-410 PBMC = peripheral blood mononuclear cells. a The values per ml of blood were extrapolated on the basis of white blood cell (WBC) number and percentage of mononuclear ceils stated for rabbits by Smith (1983) (9.79+3.21 WBC× 106/ml; 49.9% mononuclear cells).…”

Section: Discussionmentioning

confidence: 97%

Pluripotent and committed haemopoietic progenitor cells in rat peripheral blood

Ivanović

Petakov

Jovčić

et al. 1997

Comparative Haematology International

View full text Add to dashboard Cite

Abstract. The assay system for determination of haemopoietic progenitors in peripheral blood of rats is essential for potential studies on mobilisation and transplantation of circulating progenitor cells in a rat experimental model. This paper demonstrates the possibility of detection and quantification of pluripotent progenitors (Colony Forming Units-Spleen day 8-CFU-Sd8) and committed progenitors (Colony Forming Units Granulocyte Macrophage-CFU-GM and Burst Forming Units-Erythroid-BFU-E) in peripheral blood of rats in a steady state. For determination of CFU-Sd8 the 'rat to mouse' in vivo assay was used, and for committed progenitors in vitro assays on methylcellulose were employed. The CFU-Sd8 incidence ranged from 7.3 to 11.6/ml of rat blood, similar to that reported in literature for mice. The incidence of CFU-GM was found to be 59.7 + 9.4/ml which is in the range of the literature data for mice, rabbits, dogs and humans. The incidence of BFU-E in rat peripheral blood was 4.3 _+ 1/ml, which was relatively low, but could be also considered as comparable with some literature data for dogs and humans. The CFU-E were not detected by the technique used. These results confirmed the existence of circulatory blood pluripotent progenitors (CFU-Sd8) and committed (CFU-GM and BFU-E) progenitors in rat, as has been established for some other mammalian species.

show abstract

“…A decreased number of CFUs is confirmatory (but not specific) for the diagnosis MDS [15][16][17]. On the other hand, however, a normal CFU count does not role out the diagnosis of MDS.…”

Section: Pathogenesis Classification and Treatment Of Myelodysplastmentioning

confidence: 89%

“…Reticulocyte counts in MDS are normal or (more frequently) are decreased [14]. Similarly, the numbers of circulating colony-forming progenitor cells (CFUs, BFU-E) are often below normal range reflecting insufficient blood cell production (Table 1) [15][16][17][18][19].…”

Section: Pathogenesis Classification and Treatment Of Myelodysplastmentioning

confidence: 97%

See 1 more Smart Citation

Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)

Valent

Wimazal

Schwarzinger

et al. 2003

Wien Klin Wochenschr

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid disorders characterized by morphologic dysplasia in one or more cell lineages. Dysplasia in MDS is associated with insufficient production of blood cells and consecutive cytopenia(s). The natural course and prognosis of MDS vary among patients and depend on genetic defects that occur during clonal evolution. In a significant group of patients (roughly 30%) progression to secondary leukemia is observed. These patients appear to have a grave prognosis. The treatment of patients with MDS has to be adjusted to the individual situation and age in each case. In many patients, control of blast cell production by palliative cytoreduction, continuous support with red blood cells, as well as other supportive measures, seem appropriate. In other patients, however, curative therapy (chemotherapy, stem cell transplantation) should be considered. The final decision to offer curative therapy must be based on many different factors including age and the overall situation of the patient. Recently established scoring systems aimed at predicting survival and evolution of leukemia in MDS may be helpful in this regard.

show abstract

Effect of 5637-conditioned medium on peripheral blood granulocyte-macrophage progenitors in normal subjects and patients with the myelodysplastic syndrome

Cited by 15 publications

References 15 publications

Burst-forming unit–erythroid assays to distinguish cellular bone marrow failure disorders

Burst-forming unit–erythroid assays to distinguish cellular bone marrow failure disorders

Pluripotent and committed haemopoietic progenitor cells in rat peripheral blood

Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)

Contact Info

Product

Resources

About